This is a 12-week, intent-to-treat, randomized controlled trial to evaluate the impact of N-Acetylcysteine (NAC) versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM) interventions, on cannabis use among treatment-seeking adults. The primary analysis will evaluate the impact of NAC versus PBO on cannabis use during the 12-week treatment intervention with the primary outcome measure being the proportion of negative urine cannabinoid tests submitted during active treatment, compared between the two treatment groups.
Participating Nodes and Community Treatment Programs
Southern Consortium Node (Lead Node)
As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.
Formed with SAMHSA to reduce the gap between research results and treatment.